Cedars-Sinai Intellectual Property Company announced it is partnering with Oxford Science Enterprises (OSE) through a major co-investment initiative. This partnership with OSE, an independent investment company launched as a joint venture with the University of Oxford, will include the ability to co-build and co-invest in future health-tech startups coming out of Oxford.
To initiate the collaboration, Cedars-Sinai Intellectual Property Company and OSE have invested $2 million in Neu Health, a startup from the University of Oxford. This organization offers a digital smartphone-based neurology-care platform to improve outcomes for Parkinson’s disease and dementia patients. This funding follows Neu Health’s participation in Cedars-Sinai’s 10th Accelerator program last year.
The Neu Health platform, backed by more than a decade of research and clinical validation by the University of Oxford, includes a patient app linked to a care team dashboard. This platform uses unique data and AI to translate motor and non-motor symptoms and cognitive and mental health abilities into objective, actionable information for clinicians.
With increasing usage in the UK, the company will pilot its digital platform at Cedars-Sinai to expand and enter the United States market. The first 150 neurology patients are expected to start using the Neu Health app as part of the six-month pilot program.
Through the strategic partnership, the two organizations aim to foster the growth of innovative health-tech startups, expand U.S. and U.K. market reach, and plan future alliances on both sides of the Atlantic.
KEY QUOTES:
“The research produced at Oxford is of the highest caliber. We are delighted to further pursue this ongoing relationship with OSE, which will serve our patients and strengthen the academic and clinical missions of Cedars-Sinai.”
– Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai
“We are excited to strengthen our relationship with Cedars-Sinai, given our shared commitment to commercializing world-leading research and building innovative businesses. This partnership plays a critical role in accelerating our entry into the United States market, providing our companies access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies.”
– Heather Roxborough, PhD, senior partner of Health Tech at Oxford Science Enterprises
“Investing in the research and technology coming out of Oxford through our partnership with Oxford Science Enterprises is the beginning of what we hope will become a long and fruitful relationship. Together, we can work on furthering Cedars-Sinai’s mission of providing patients around the world the best care possible.”
– James D. Laur, JD, chief executive of Cedars-Sinai Intellectual Property Company
